For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

Targeting TNF-alpha in HS

Overexpression of cytokines, including TNF-alpha, plays a key role in fueling inflammation2,3

Moderate to severe HS is a chronic immune-mediated skin disease that can be progressive and debilitating.2,4-7


Hair follicles become plugged with keratin, then rupture, leaking contents into connective tissue.3,8


An inflammatory response follows, fueled by TNF-alpha and other proinflammatory cytokines, and an inflammatory nodule or abscess forms.2,3


The wound heals, but the process becomes chronic, which may lead to sinus tracts and hypertrophic scars.8

HS in the axillae

HUMIRA specifically targets and blocks TNF-alpha which contributes to the inflammation that causes the abscesses, inflammatory nodules and draining fistulas in HS.1

The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown.1